A
PTGX icon

AlphaQuest’s Protagonist Therapeutics PTGX Stock Holding History

AlphaQuest’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,617
Closed -$141K – 1572
2025
Q4 		$141K Sell
1,617
-1
-0.1% -$82 0.01% 1597
2025
Q3 		$107K Buy
+1,618
New +$92K 0.01% 1698
2025
Q2 		– Sell
-2,704
Closed -$131K – 2152
2025
Q1 		$131K Buy
2,704
+527
+24% +$22.1K 0.01% 1183
2024
Q4 		$84K Sell
2,177
-21,770
-91% -$949K 0.01% 1143
2024
Q3 		$1.08M Buy
23,947
+21,516
+885% +$869K 0.1% 328
2024
Q2 		$84.2K Sell
2,431
-3,469
-59% -$102K 0.01% 970
2024
Q1 		$171K Buy
+5,900
New +$161K 0.03% 686

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

AlphaQuest's PTGX Position: Q1 2026 in Review

AlphaQuest sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 1,617 shares — an estimated $141K sold.

AlphaQuest first reported a position in PTGX in Q1 2024 and held it in 7 quarters. The position peaked at $1.08M in Q3 2024. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • AlphaQuest reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 1,617 Protagonist Therapeutics shares in Q1 2026, an estimated $141K.
  • AlphaQuest first reported a position in Protagonist Therapeutics in Q1 2024 and held it in 7 quarters.
  • AlphaQuest's Protagonist Therapeutics position peaked at $1.08M in Q3 2024.
  • 320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.